Author:
Fiorentini Giammaria,Aliberti Camillo,Coschiera Paolo,Casadei Virginia,Mulazzani Luca,Baldelli Anna Maria,Mambrini Andrea,Rossi David
Publisher
Springer International Publishing
Reference31 articles.
1. Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003;8(6):521–30.
2. Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol. 2009;19(4):222–8.
3. Bergh J, Jönsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001;40(2–3):253–81.
4. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;15(2):CD003372.
5. Heidemann E, Stoeger H, Souchon R, Hirschmann WD, Bodenstein H, Oberhoff C, Fischer JT, Schulze M, Clemens M, Andreesen R, Mahlke M, König M, Scharl A, Fehnle K, Kaufmann M. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol. 2002;13(11):1717–29.